CASE REPORT | VOLUME 3, ISSUE 3 | OPEN ACCESS DOI: 10.23937/2469-584X/1510047

A Case of Serial Liver Injury Induced by Plant Food Supplements in a Young Healthy Man

Gianluca Cappelleri1, Enrico Sangiovanni2 and Mario Dell'Agli2

1Anesthesia Department, Istituto Ortopedico G. Pini, Milan, Italy

2Laboratory of Pharmacognosy, Department of Pharmacological and Biomolecular Sciences of Milan, University of Milan, Italy

*Corresponding author: Prof. Mario Dell'Agli, Ph.D, Laboratory of Pharmacognosy Department of Pharmacological and Biomolecular Sciences of Milan, University of Milan, Italy, Tel: +390250318398, E-mail:

Received: April 08, 2017 | Accepted: July 06, 2017 | Published: July 08, 2017

Citation: Cappelleri G, Sangiovanni E, Dell’Agli M (2017) A Case of Serial Liver Injury Induced by Plant Food Supplements in a Young Healthy Man. J Clin Gastroenterol Treat 3:047.

Copyright: © 2017 Cappelleri G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Serial liver injury, Plant food supplements, Case report, Scutellaria spp., Skullcap


The use of botanicals is increasingly throughout the world. They are ingredients of different types of products, such as herbal medicinal products, Plant Food Supplements (PFS), and functional foods. They are commonly taken to promote health and treat or prevent diseases, even if, in most of cases, there is no clear evidence of their clinical efficacy. In recent years, several reports have highlighted the beneficial effects of botanicals or PFS in the prevention of some chronic diseases [1,2]. But these positive effects are accompanied by the increased incidence of hepatic damage caused by herbal medicines, including PFS [3-7]. We are presenting two repeated cases of acute hepatitis occurred in the same patient for two consecutive years, after taking the same PFS.

Case Presentation

A 40-year-old male, healthy, with no morbidities, was hospitalized with nausea, vomiting, pruritus, and headache. Symptoms were started two days before. At clinical examination skin and sclera were yellow; these signs in association with symptoms were suggestive for acute hepatitis. There was no other sign of chronic liver disease. He reported a 14-day ongoing natural therapy of two different PFS (once a day each) to prevent seasonal allergy and a recent consumption of raw fish. No other medical treatment was taking by the patient in the same period. PFS composition is reported in Table 1.

Table 1: Pfs ingredients, standardization and in vivo Cyp3a4 modulation. View Table 1

Laboratory test revealed normal blood count and basic metabolic panel. Liver tests showed Alanine Aminotransferase (ALT) level of 2605 IU/L, aspartate aminotransferase of 918 IU/L, and a total bilirubin of 17.35 mg dl-1 (directed 13.44 mg dl-1) (Table 2). Both hepatitis B and C testing were negative.

Table 2: The evolution of the liver enzymes at the first and second year. View Table 2

Instrumental investigations to rule out all other causes of jaundice were performed. Imaging studies for biliary obstruction were negative. He was discharged with the diagnosis of “food acute hepatitis” and a bland diet and biliary salt therapy was provided. Symptoms disappeared in 3 months, with the normalization of serum liver enzyme (Table 2).

One year later, in the same season, patient was re-admitted because of jaundice, with similar symptoms described before, including nausea, vomiting, headache, and yellow skin. On admission Alanine Aminotransferase (ALT) level was of 2158 IU/L and the aspartate aminotransferase was of 924 IU/L, while total bilirubin was 10.12 mg dl-1 (Table 2). He reported the consumption of the same PFS of the previous year (PFS ingredients are reported in Table 1), started 10 days before. PFS consumption was immediately interrupted and the patient was treated again with a bland diet and biliary salt. This new episode of acute hepatitis was resolved in further 3 months with the complete normalization of serum liver enzyme. The new imaging showed the presence of mild steatosis.


In this report, the etiology of the acute liver injury is resulted unequivocal the second year considering the consumption of the same PFS of the previous year. Identifying any toxic component(s) in herbal mixtures is a major problem since such supplements contain multiple ingredients. Each component may not be pure compounds and not all components occurring in the extracts could be listed as ingredients. Among all the botanicals present in the PFS of this case, hepatotoxic reactions have been reported after ingestion of Scutellaria spp. (skullcap)-containing preparations, alone or combined with other plant extracts [8,9]. Accordingly, the Food and Drug Administration (FDA) has listed skullcap as an herb of undefined safety. Moreover, some skullcap preparations available from wholesale suppliers contain species belonging to the Teucrium genus, including the hepatotoxic plant Germander (Teucrium chamaedrys L.) [10]. This observation strongly highlights the need for an accurate identification of the plant material [11]. LC-MS/MS analysis on the acetone extract prepared from the PFS capsules allowed us to exclude the presence of teucrin A, which is the main hepatotoxic neo-clerodane occurring in Germander.

Neo-clerodane diterpenoids with cytotoxic activity have been identified from the whole plant of Scutellaria spp. and from the aerial parts of Scutellaria baicalensis [12], thus suggesting that these compounds, which effects in humans have not been still identified, could have toxic effects comparable to those exerted by teucrin A.

Although skullcap seems to be the candidate mostly responsible for the adverse effect, the contribution of other botanicals occurring in both the formulations cannot be excluded.

Hepatotoxicity of green tea preparations, mainly containing unusual concentration of catechins, has been reviewed [7,13]. Although the bioavailability of catechins is low after oral administration, plasma levels can reach toxic levels under fasting or repeated administration. Green tea hepatotoxicity has been imputed to the capability of Epigallocatechin-3-O-Gallate (EGCG) or its metabolites to induce oxidative stress in the liver [13].

Several herbal ingredients, occurring within both the above-mentioned PFS, have been identified as modulators of various cytochrome P450 enzymes, particularly CYP3A4 [9]. CYP3A4 modulators could potentiate the intrinsic hepatotoxicity of other substances, including neo-clerodane diterpenoids, by an increased conversion to toxic metabolites. Table 1 reports the in vivo modulation of cytochromes by ingredients included in PFS.

The hepatocellular (not cholestatic) injury with the combination of increased aminotransferase and serum total bilirubin could lead to consider the patient as a Hy's law case [14]. Unfortunately, botanicals are not included among Drug-Induced-Liver-Injury (DILI) [15], but considering symptoms and the clinical history of the patient, we cannot exclude a Hy's law case.

The current case report suggests the potential hepatotoxicity of some PFS commercially available; since they are accessible to the public and used as self-medication, the risk of adverse effects is high. This highlights the need for an active surveillance on PFS to provide detailed information on their safety. Further, the possibility of interactions among PFS ingredients before commercialization should be considered as well as new data on the safety of neo-clerodanes in skullcap.


The authors thank Prof. D. Caruso and Mr. F. Giavarini for LC-MS analysis.

Conflicts of Interest



  1. Dell'Agli M, Di Lorenzo C, Badea M, Sangiovanni E, Dima L, et al. (2013) Plant food supplements with anti-inflammatory properties: a systematic review (I). Crit Rev Food Sci Nutr 53: 403-413.

  2. Di Lorenzo C, Dell'Agli M, Badea M, Dima L, Colombo E, et al. (2013) Plant food supplements with anti-inflammatory properties: a systematic review (II). Crit Rev Food Sci Nutr 53: 507-516.

  3. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A (2013) Herbal hepatotoxicity: a critical review. Br J Clin Pharmacol 75: 630-636.

  4. Teschke R, Wolff A, Frenzel C, Schulze J, Eickhoff A (2012) Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int 32: 1543-1556.

  5. Garcia-Cortes M, Robles-Diaz M, Ortega-Alonso A, Medina-Caliz I, Andrade RJ (2016) Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. Int J Mol Sci 17: 537.

  6. Haslan H, Suhaimi FH, Das S (2015) Herbal Supplements and Hepatotoxicity: A Short Review. Nat Prod Commun 10: 1779-1784.

  7. Mazzanti G, Di Sotto A, Vitalone A (2015) Hepatotoxicity of green tea: an update. Arch Toxicol 89: 1175-1191.

  8. Chalasani N, Vuppalanchi R, Navarro V, Fontana R, Bonkovsky H, et al. (2012) Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med 156: 857-860.

  9. Bunchorntavakul C, Reddy KR (2013) Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 37: 3-17.

  10. Phillipson JD, Anderson LA (1984) Herbal remedies used in sedative and anti-rheumatic preparations: Part 1. Pharm J 233: 80-82.

  11. Sandasi M, Vermaak I, Chen W, Viljoen AM (2014) Skullcap and germander: preventing potential toxicity through the application of hyperspectral imaging and multivariate image analysis as a novel quality control method. Planta Med 80: 1329-1339.

  12. Hussein AA, De La Torre M, Jimeno ML, Rodriguez B, Bruno M, et al. (1996) A neo-clerodane diterpenoid from Scutellaria baicalensis. Phytochemistry 43: 835-837.

  13. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, et al. (2009) Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 65: 331-341.

  14. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, et al. (2014) Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 147: 109-118.

  15. United States department of health and human service, Food and Drug Administration (FDA) (2009) Guidance for Industry Drug-Induced-Liver-Injury: Premarketing Clinical Evaluation.

  16. Yoshioka M, Ohnishi N, Sone N, Egami S, Takara K, et al. (2004) Studies on interactions between functional foods or dietary supplements and medicines. III. Effects of ginkgo biloba leaf extract on the pharmacokinetics of nifedipine in rats. Biol Pharm Bull 27: 2042-2045.

  17. Ohnishi N, Kusuhara M, Yoshioka M, Kuroda K, Soga A, et al. (2003) Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull 26: 1315-1320.

  18. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, et al. (2008) Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 24: 591-599.

  19. Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD (2003) Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 23: 576-581.

  20. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, et al. (2006) Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 46: 1290-1298.

  21. Su T, Mao C, Yin F, Yu Z, Lin Y, et al. (2013) Effects of unprocessed versus vinegar-processed Schisandra chinensis on the activity and mRNA expression of CYP1A2, CYP2E1 and CYP3A4 enzymes in rats. J Ethnopharmacol 146: 734-743.

  22. Tian X, Cheng ZY, Jin H, Gao J, Qiao HL (2013) Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats. Evid Based Complement Alternat Med 2013: 179643.

  23. 23. Misaka S, Kawabe K, Onoue S, Werba JP, Giroli M, et al. (2013) Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats. Drug Metab Pharmacokinet 28: 514-518.

  24. Mooiman KD, Maas-Bakker RF, Hendrikx JJ, Bank PC, Rosing H, et al. (2014) The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel. J Pharm Pharmacol 66: 865-874.

  25. Engdal S, Nilsen OG (2009) In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res 23: 906-912.

  26. Sridhar V, Surya Sandeep M, Ravindra Babu P, Naveen Babu K (2014) Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using felodipine and hesperetin in combination in Wistar rats and everted rat gut sacs in vitro. Phytother Res 28: 699-705.